Factors Affecting Extracellular Vesicles Based Drug Delivery Systems

Gaurav, Isha; Thakur, Abhimanyu; Iyaswamy, Ashok; Wang, Xuehan; Chen, Xiaoyu; Yang, Zhijun

doi:10.3390/molecules26061544

Cited by 52 publications

(41 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, EVs receive special attention as physiological delivery tools, the usage of which reduces the side effects of treatment. However, the latter application is still fraught with many challenges, including enhancing their biological effectiveness and directing them towards desired target cells [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Antibodies Enhance the Suppressive Activity of Extracellular Vesicles in Mouse Delayed-Type Hypersensitivity

et al. 2021

View full text Add to dashboard Cite

Previously, we showed that mouse delayed-type hypersensitivity (DTH) can be antigen-specifically downregulated by suppressor T cell-derived miRNA-150 carried by extracellular vesicles (EVs) that target antigen-presenting macrophages. However, the exact mechanism of the suppressive action of miRNA-150-targeted macrophages on effector T cells remained unclear, and our current studies aimed to investigate it. By employing the DTH mouse model, we showed that effector T cells were inhibited by macrophage-released EVs in a miRNA-150-dependent manner. This effect was enhanced by the pre-incubation of EVs with antigen-specific antibodies. Their specific binding to MHC class II-expressing EVs was proved in flow cytometry and ELISA-based experiments. Furthermore, by the use of nanoparticle tracking analysis and transmission electron microscopy, we found that the incubation of macrophage-released EVs with antigen-specific antibodies resulted in EVs’ aggregation, which significantly enhanced their suppressive activity in vivo. Nowadays, it is increasingly evident that EVs play an exceptional role in intercellular communication and selective cargo transfer, and thus are considered promising candidates for therapeutic usage. However, EVs appear to be less effective than their parental cells. In this context, our current studies provide evidence that antigen-specific antibodies can be easily used for increasing EVs’ biological activity, which has great therapeutic potential.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibodies Enhance the Suppressive Activity of Extracellular Vesicles in Mouse Delayed-Type Hypersensitivity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recently, EVs have emerged as a promising NDS with huge application in cancer therapy as well as diagnosis. A detailed review of the factors reacting with EV-based drug delivery systems has been reported by our group previously [151]. Interestingly, the surface modification of EVs has a great potential to achieve the targeting ability [152].…”

Section: Conjugation Of Peptides and Extracellular Vesicles (Cpevs) For Cancer Therapymentioning

confidence: 95%

Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer

Gaurav

Wang

Thakur³

et al. 2021

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Peptides are strings of approximately 2–50 amino acids, which have gained huge attention for theranostic applications in cancer research due to their various advantages including better biosafety, customizability, convenient process of synthesis, targeting ability via recognizing biological receptors on cancer cells, and better ability to penetrate cell membranes. The conjugation of peptides to the various nano delivery systems (NDS) has been found to provide an added benefit toward targeted delivery for cancer therapy. Moreover, the simultaneous delivery of peptide-conjugated NDS and nano probes has shown potential for the diagnosis of the malignant progression of cancer. In this review, various barriers hindering the targeting capacity of NDS are addressed, and various approaches for conjugating peptides and NDS have been discussed. Moreover, major peptide-based functionalized NDS targeting cancer-specific receptors have been considered, including the conjugation of peptides with extracellular vesicles, which are biological nanovesicles with promising ability for therapy and the diagnosis of cancer.

show abstract

“…Recently, several studies have proposed the use of exosomes as potential DDSs for therapeutic application in cancer to overcome the problems associated with synthetic DDSs. These EVs serve as efficient vehicles for tumor-targeted delivery because their biological origin reduces the immune response, they can cross biological barriers including the blood brain barrier (BBB) [ [165] , [166] , [167] , [168] ], and can transfer their cargo to nearby or distant cells. In addition there are adhesion proteins on their surface, and they are small in size with excellent stability, biocompatibility and safety [ 156 , 161 , 162 , 169 ].…”

Section: Exosome-based Delivery Systems For Cancer Therapeuticsmentioning

confidence: 99%

Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics

Thakur

Parra

Motallebnejad

et al. 2022

Bioactive Materials

Self Cite

153

103

View full text Add to dashboard Cite

Cancer is a deadly disease that is globally and consistently one of the leading causes of mortality every year. Despite the availability of chemotherapy, radiotherapy, immunotherapy, and surgery, a cure for cancer has not been attained. Recently, exosomes have gained significant attention due to the therapeutic potential of their various components including proteins, lipids, nucleic acids, miRNAs, and lncRNAs. Exosomes constitute a set of tiny extracellular vesicles with an approximate diameter of 30–100 nm. They are released from different cells and are present in biofluids including blood, cerebrospinal fluid (CSF), and urine. They perform crucial multifaceted functions in the malignant progression of cancer via autocrine, paracrine, and endocrine communications. The ability of exosomes to carry different cargoes including drug and molecular information to recipient cells make them a novel tool for cancer therapeutics. In this review, we discuss the major components of exosomes and their role in cancer progression. We also review important literature about the potential role of exosomes as vaccines and delivery carriers in the context of cancer therapeutics.

show abstract

Factors Affecting Extracellular Vesicles Based Drug Delivery Systems

Cited by 52 publications

References 156 publications

Antibodies Enhance the Suppressive Activity of Extracellular Vesicles in Mouse Delayed-Type Hypersensitivity

Antibodies Enhance the Suppressive Activity of Extracellular Vesicles in Mouse Delayed-Type Hypersensitivity

Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer

Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics

Contact Info

Product

Resources

About